Two new classification systems for hematopoietic tumors have recently been published; in the International Consensus Classification (ICC), PEL is no longer recognized as a separate entity and is instead included in a broader category of AML with mutated TP53 [3]; in the proposed 5th edition of the WHO document, The WHO alters the terminology from PEL to acute erythroid leukemia (AEL) [4]. This evidence concerns the gene TP53 and primary effusion lymphoma.